Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-12-16-Speech-2-265"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20031216.6.2-265"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, ladies and gentlemen, to begin with, I should like to join in thanking the rapporteurs for their efforts towards bringing this important dossier to a successful conclusion. I am very happy that this Parliament, together with the Council, has succeeded in refining the Commission’s proposals substantially, which were indeed very sweeping and liberal at first. What is being served up is of course a compromise, with some elements that are good and some that are not so good. In any case, it is a good thing that all medicinal products
falling under EU regulations will have to comply with the same criteria of quality, safety and efficacy.
Another thing of great importance is that commercial advertising is still outlawed. Do you recall the original Commission proposals, which, as a pilot project, sought to permit advertising of medicinal products for AIDS, asthma and diabetes? In my view, patient information must be guaranteed to be reliable and objective. It is logical, therefore, that this flow of information be organised and coordinated by the public sector in the first instance. I am pleased that the Commission is now being given the task of putting forward proposals, based on an overview of the current situation, to bring about improved, objective information provision, which, in my opinion, will have to include information and sales via the Internet.
The duration of data protection, however, is less positive, in my opinion. After all, in comparison with the United States or Japan, for example, the period of protection for medicinal products
in Europe is extremely long. Admittedly, it is a good thing that, from the eighth year, the generic pharmaceuticals industry will be able to start some preparatory work in order that it may place generic medicinal products
on the market from the tenth year. In my opinion, however, there are too many possibilities for an extra year’s protection to be added, for example when a new indication can be proved. In my view, this was entirely unnecessary.
I sincerely hope, therefore, that the Commission will monitor the situation closely to ensure that these possibilities are not abused. Finally, I also regret the absence of an amendment on Doha."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples